SkinBioTherapeutics

Activities: Research & Development Microbiology

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Ingredients

How to leverage the gut-skin axis to address health conditions

Food supplements: a better way to utilise the body’s microbiome? Stuart J. Ashman, CEO, and Dr Catherine O’Neill, CSO, SkinBioTherapeutics, investigate

Stuart Ashman joins SkinBioTherapeutics

Nutraceutical

Study on humans demonstrates efficacy of SkinBiotix

The proprietary technology by SkinBioTherapeutics is derived from probiotic bacteria
Drug Delivery

Bacteria as ingredients in skincare products: a manufacturing challenge

The concept of friendly bacteria is now well embedded in the public’s imagination, and various food and drinks containing probiotics have been a huge commercial success, reports Cath O'Neill, CEO, SkinBioTherapeutics
Subscribe now